Announcements Trials
Browse Landscape

Phase

Phase 2 54Phase NA 41Phase 1 18Phase 3 13Phase EARLY_PHASE1 9Phase 1/2 8Phase 4 3Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Squamous Cell Carcinoma of Head and Neck 4Lung Neoplasms 4Oropharyngeal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Mouth Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Colorectal Neoplasms 2Carcinoma 2Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stage II Prostate Adenocarcinoma 1Sarcoma, Ewing 1Renal Pelvis and Ureter Urothelial Carcinoma 1Recurrence 1Rectal Neoplasms 1Prostatic Neoplasms 1Prostate Adenocarcinoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Nasopharyngeal Carcinoma 1Muscle Invasive Bladder Urothelial Carcinoma 1Multiple Endocrine Neoplasia Type 1 1Lymphoma, B-Cell, Marginal Zone 1Lymphoid Interstitial Pneumonia 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1

Interventions

Docetaxel 7acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 5Prednisone 5Androgen Antagonists 5gallium 68 PSMA-11 4enzalutamide 3bicalutamide 3Triptorelin Pamoate 3Radiosurgery 3Leuprolide 3Goserelin 32-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 3abiraterone 2Zoledronic Acid 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Mitoxantrone 2Flutamide 2Celecoxib 2Abiraterone Acetate 2satraplatin 1relugolix 1pertuzumab 1nilutamide 1maltodextrin 1luprolide acetate gel depot 1histrelin 1genistein combined polysaccharide 1fluciclovine F-18 1darolutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Prostatic Neoplasms × Magnetic Resonance Spectroscopy × Clear all
NCT02673151 2022-01-13

68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment

Stanford University

Phase 2/3 Completed
61 enrolled 10 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡